X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Voquezna Triple Pack
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Phathom Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 24, 2022
Details:
The proceeds will be used to execute the ongoing launch of Voquezna (vonoprazan), an oral small molecule potassium-competitive acid blocker (PCAB), approved in the U.S. for the treatment of adults with Erosive Esophagitis and help fund future clinical development programs.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Voquezna
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 14, 2023
Details:
Voquezna (vonoprazan) is an oral small molecule potassium-competitive acid blocker (PCAB). It is being developed for the treatment of Non-Erosive Gastroesophageal Reflux Disease.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Voquezna
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
Voquezna (vonoprazan) is an oral small molecule potassium-competitive acid blocker (PCAB). It is being developed for the treatment of erosive GERD and relief of associated heartburn.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Voquezna
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) contain vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB) co-packaged with antibiotics. It has been approved by FDA for the treatment of H. pylori infection in adults.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Voquezna Triple Pak
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
Vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease), also referred to as erosive esophagitis, to the U.S. Food and Drug Administration (FDA).
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Vonoprazan tablet is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of Erosive GERD.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: TAK-438
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
Vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease), also referred to as erosive esophagitis, to the U.S. Food and Drug Administration (FDA).
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
Phathom intends to use the net proceeds from the proposed offering to fund the clinical development of vonoprazan, an oral small molecule potassium-competitive acid blocker, pre-commercial activities and commercialization expenses.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $130.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 23, 2023
Details:
Vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease), also referred to as erosive esophagitis, to the U.S. Food and Drug Administration (FDA).
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2023
Details:
Vonoprazan, a novel potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. Drug is under review for the treatment of erosive esophagitis.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
Vonoprazan is a potassium-competitive acid blocker that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders and as an adjunct to Helicobacter pylori eradication.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 01, 2022
Details:
Vonoprazan is an investigational first-in-class potassium-competitive acid blocker (PCAB) from a novel class of medicines that block acid secretion in the stomach.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), is being evaluated to address the needs of patients affected by a range of acid-related gastrointestinal disorders, including non-erosive gastroesophageal reflux disease (NERD).
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
Voquezna (vonoprazan) new treatment options contain antibiotics conveniently packaged with vonoprazan, a novel potassium-competitive acid blocker (PCAB) and the first innovative acid suppressant from a new drug class approved in the U.S. in over 30 years.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Voquezna
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Phathom Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) is an orally administered potassium-competitive acid blocker from a new class of acid suppressant agents and under development for treatment of erosive esophagitis and non-erosive gastroesophageal reflux disease.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Voquezna Triple Pack
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
The clinical data from Phathom being presented include Phase 3 results evaluating vonoprazan as investigational monotherapy in erosive esophagitis (EE) and data on the pharmacodynamics and pharmacokinetics of vonoprazan compared to lansoprazole, a proton pump inhibitor.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
The signing of this agreement both validates the belief in the blockbuster opportunity of Voquenza (vonoprazan) and provides near-term, non-dilutive funding for continued development activities and upcoming commercial launch.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Voquenza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley & Co.
Deal Size: $260.0 million Upfront Cash: $100.0 million
Deal Type: Agreement May 04, 2022
Details:
Vaquezna (vonoprazan)TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker, and have demonstrated superior eradication rates vs. lansoprazole-based triple therapy in overall patient population of pivotal Phase 3 trial.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Vaquezna Triple Pak
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
VOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple therapy in the overall patient population of the pivotal Phase 3 trial.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Voquezna Dual Pak
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
The NDA is based on positive data previously announced from PHALCON-EE trial that enrolled 1,024 patients with EE in U.S. and Europe, compared vonoprazan to lansoprazole, a standard of care PPI, in healing and maintenance of healing of EE, and heartburn symptom relief.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Takecab
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
Details:
Vonoprazan has shown the potential to have rapid, potent, and durable anti-secretory effects as a single agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2021
Details:
Vonoprazan is an investigational, oral small molecule potassium-competitive acid blocker (P-CAB), demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus lansoprazole (PREVACID®), a proton pump inhibitor (PPI).
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
This loan facility will strengthens key catalysts, including data from the pivotal PHALCON-EE Phase 3 trial of vonoprazan for the treatment of erosive esophagitis and improve potential for US commercial launch and provides Phathom with additional financial flexibility.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 20, 2021
Details:
Under the terms of the agreement, should the drug receive FDA approval for its lead product vonoprazan. Catalent will undertake the commercial manufacturing and packaging of the product at its large-scale oral solid dose manufacturing site in Winchester, Kentucky.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Phathom Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 16, 2021
Details:
Phathom Pharmaceuticals has submitted two NDAs to the U.S. FDA for the use of vonoprazan in combination with amoxicillin and clarithromycin and vonoprazan in combination with amoxicillin as a treatment for Helicobacter pylori (H. pylori) infection in adults.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Vonoprazan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
Takeda has applied for approval to manufacture and market TAKECAB® OD 10 mg and TAKECAB® OD 20 mg as additional formulations of TAKECAB® 10 mg and TAKECAB® 20 mg, developed by Takeda for treating acid-related disease.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Takecab
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
Phathom announced to resume enrollment and randomization of new patients in their PHALCON-EE and PHALCON-HP Phase 3 studies of vonoprazan that they have temporarily paused in March due to the COVID-19 pandemic.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!
